Analysis of genomic sequence data for 16 other cancer types (by TCGA, ICGC and other large-scale genomic efforts) identified an incidence of 0.5% to 13%, which equates to over 54,000 new cases of HER2-amplified cancers per year in the USA alone (see Additional file 10). The gene discussed is ERBB2; the disease is cancer.